New combo shot aims to reignite immune attack on tough melanoma
NCT ID NCT04796194
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of an injected drug (LTX-315) and an intravenous immunotherapy (pembrolizumab) in 23 people with advanced melanoma that no longer responded to standard PD-1/PD-L1 inhibitors. The goal was to see if the combination could shrink tumors or slow the disease. Participants had tumors that could be injected directly, such as those under the skin or in lymph nodes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LTX-315 (injected into tumors) combined with pembrolizumab (IV infusion)
What this could lead to
If successful, this combination could offer a new treatment option for advanced melanoma patients whose cancer no longer responds to standard immunotherapy.
What could go wrong
This is a small, early-phase study with only 23 participants, so results may not apply broadly. The treatment involves injections into tumors and may cause side effects like pain, swelling, or immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital
Lørenskog, Norway
-
Centre Hospitalier Regional Universitaire De Lille
Lille, France
-
Clínica Universidad de Navarra
Pamplona, Spain
-
Gustave Roussy Cancer Campus
Paris, France
-
Hospital Lyon Sud
Pierre-Bénite, France
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Levine Cancer Institute - Atrium Health
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Centre
Houston, Texas, 77030, United States
-
Oslo University Hospital--Radiumhospitalet
Oslo, Norway
-
University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States